T. Rowe Price CEO: $20B in client outflows ‘clearly the missing ingredient’

T. Rowe's CEO Rob Sharps, in discussing the firm's second quarter results, said outflows should get better in 2024 and that the company is poised to return to organic growth in 2025.

Long Covid is wreaking havoc on the workforce. Here’s how businesses can respond.

Austin ranked nation’s No. 2 BBQ city — right after San Antonio

Birmingham Commercial Exchange platform launches for real estate agents

Mixed-use project at former Patrick J’s site comes back to OSU-area review board

3 large hospital systems sue Oregon over alleged ‘warehousing’ of mental health patients

Triple net investing hits home at CREJ event

Castle Rock-based construction firm announces new president

Shopoff Realty Investments submits 48-townhome project proposal for former Bee parking lot

T. Rowe Price CEO: $20B in client outflows ‘clearly the missing ingredient’

Previous Federated Hermes CEO talks strength in numbers, both Q2 results and family dynamics

Next Biogen to buy DFW rare disease firm for $7.2B

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

UWM startup Pantherics secures $255K more government funding

Capital Bank kick-starts foundation with $250K in grants

Lawsuit targets Nvidia for ‘misleading’ investors over crypto collapse

Although at a slower pace, Philadelphia-area health systems continue to make deals

Virtual to reality: Online retailers are getting into the brick-and-mortar business

JPMorgan Chase’s D.C.-based health care arm invests $25M in Kindbody, CEO lays out vision for 2023

MENU

FirstStar Group

More Stories

Clearwater cybersecurity company is a funding standout in Florida

Previous Federated Hermes CEO talks strength in numbers, both Q2 results and family dynamics

Next Biogen to buy DFW rare disease firm for $7.2B

firststargroup

Related Posts

Suggested Posts

MENU

FirstStar Group

More Stories